Jolanda de Vries
Radboud Institute for Molecular Life Sciences (RIMLS); Radboud University Nijmegen Medical Centre, The Netherlands

Jolanda de Vries (PhD) is a Professor at the Department of Tumor Immunology at the Nijmegen Centre for Molecular Life Sciences. She was one of the pioneers to translate dendritic cell biology into potential clinical applications. The first clinical phase I/II studies in which patients were vaccinated with DCs loaded with tumor-specific peptides were initiated in 1997. She also developed a novel immuno-monitoring assay that is highly predictive for extended survival after vaccination with DCs. Her primary scientific interest continues along the line of DC-immunotherapy and in particular the migration and imaging of DC. For example, in-vivo imaging of ex-vivo labeled cells using MRI. New opportunities for example preventive vaccination of patients prone to develop cancer at an early age are explored.

https://www.radboudumc.nl/en/research/departments/tumor-immunology